KW-2149

KW-2149 (KT-6149) is a Mitomycin C (HY-13316) analogue activated by serum. KW-2149 can interact with DNA. KW-2149 exhibits antitumor activity. KW-2149 has pulmonary toxicity KW-2149 can be used for the research of cancer, such as leukemia[1][2].

Product Specifications

CAS Number

[118359-59-4]

Product Name Alternative

KT-6149

UNSPSC

12352005

Target

DNA Alkylator/Crosslinker; Drug Derivative

Related Pathways

Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Smiles

CO[C@]12N(C[C@@]3([H])[C@]2([H])N3)C4=C(C(C(NCCSSCCNC(CC[C@H](N)C(O)=O)=O)=C(C4=O)C)=O)[C@H]1COC(N)=O

Molecular Formula

C24H34N6O8S2

Molecular Weight

598.69

References & Citations

[1]Tsuruo T, et al. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2- (gamma-L-glutamylamino) ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol. 1990;27 (2) :89-93.|[2]Schrijvers D, et al. KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. Anticancer Drugs. 1999 Aug;10 (7) :633-9|[3]McAdam SR, et al. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C) : DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55 (11) :1777-83.